CHICAGO--(BUSINESS WIRE)--Owing to a ramp-up of clinical trial operations, manufacturing processes for the E2 Collector and expanded development of a groundbreaking screening system for the early detection of uterine cancer, CytoCore, Inc. (OTCBB:CYCR) reported a loss for the 3rd quarter ended September 30, 2006.
